New Data Highlights Superior Efficacy and Tolerability of Avextra 10/10 in Treating Chemotherapy-Induced Neuropathic Pain
Bensheim, Germany – 13 March 2025 – At its annual congress in Frankfurt, Germany, this week, researchers from the German Pain Association will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra Pharma, a pioneering German biotech focused on the research and development of Cannabis-Based Medicines (CBMs).
The OCEAN-R study showcases the efficacy and safety of Avextra 10/10, a balanced ratio 1:1 THC/CBD extract, in addressing Chemotherapy-Induced Neuropathic Pain (CINP).